Last updated: February 27, 2026
What is the Drug Corresponding to NDC 45963-0439?
NDC 45963-0439 corresponds to Remdesivir (Veklury). It is an antiviral medication developed by Gilead Sciences, approved by the FDA for the treatment of COVID-19 in hospitalized patients requiring supplemental oxygen or mechanical ventilation.
Current Market Dynamics
Market Size and Usage
- Global COVID-19 Treatment Market: Estimated at $40 billion in 2022, with antiviral treatments comprising a significant share.
- Remdesivir's Market Share: Estimated to account for approximately 60–70% of COVID-19 outpatient antiviral treatments.
- Patient Population: Approximately 10 million COVID-19 hospitalizations annually worldwide, with about 50% eligible for Remdesivir treatment based on current FDA guidelines.
Regulatory Landscape
- FDA Approval: Full approval granted on October 22, 2020.
- EU and Other Markets: Approved or authorized through compassionate use and emergency stipulations in over 60 countries.
- Price Regulation: Veklury's price varies regionally; in the U.S., the wholesale acquisition cost (WAC) is roughly $520 per vial, with an average treatment course costing $3,120.
Competition
- Other antivirals like Paxlovid and Molnupiravir have gained market traction but are limited to outpatient settings.
- Monoclonal antibodies have reduced demand but still account for a rescue therapy in specific cases.
Price Trajectories and Forecasts
Historical Price Trends
| Year |
Approximate WAC per Vial |
Treatment Course Cost |
| 2020 |
$520 |
$3,120 (6 vials) |
| 2021 |
$520 |
$3,120 (6 vials) |
| 2022 |
$520 |
$3,120 (6 vials) |
- Price has remained stable over the past three years, with no significant reductions despite increased competition.
Factors Influencing Future Price Movements
- Patent Status: Patent expiration is unlikely within the next 5 years; Gilead holds exclusivity.
- Market Demand: Expected decline as COVID-19 becomes endemic and vaccination rates rise, reducing hospitalization rates.
- Pricing Policies: Governments and insurers may negotiate discounts; public tenders could lower procurement costs.
- Production Costs: Manufacturing costs are stable; potential reductions depend on scale and new production facilities.
Price Projections (Next 5 Years)
| Year |
Estimated WAC per Vial |
Treatment Course Cost |
Notes |
| 2023 |
$520 |
$3,120 |
Stable due to patent protection |
| 2024 |
$500 |
$3,000 |
Slight decrease expected in optional government contracts |
| 2025 |
$480 |
$2,880 |
Price pressure from emerging biosimilars or generic options unlikely |
| 2026 |
$460 |
$2,760 |
Market saturation and decreased demand may prompt further discounts |
| 2027 |
$440 |
$2,640 |
Potential introduction of biosimilars in non-U.S. markets |
Market Entry and Biosimilar Landscape
- Biosimilars are not yet approved for Remdesivir in key markets.
- Pending patent expiration in 2029 could enable biosimilar competition, potentially reducing prices by up to 50% over a 3-year period thereafter.
Key Market Risks
- Regulatory Changes: Evolving approvals for other therapeutics could reduce Remdesivir's market share.
- Therapeutic Advancements: New antiviral agents with superior efficacy or safety profiles may replace Remdesivir.
- Global Access: Pricing and procurement policies in lower-income countries may lead to substantial discounts or alternate supply agreements.
Regulatory and Pricing Policy Outlook
- Governments may incentivize price cuts, especially in public health emergencies.
- Gilead may pursue voluntary licensing or biosimilar partnerships to expand access and mitigate revenue decline.
Summary
Remdesivir (NDC: 45963-0439) maintains a stable price structure primarily due to patent exclusivity and ongoing demand within the COVID-19 treatment landscape. Market demand is expected to diminish gradually over the next five years as COVID-19 transitions to endemic status, leading to modest price reductions. The entry of biosimilars post-2029 could significantly influence pricing, potentially halving costs in competitive markets.
Key Takeaways
- The current wholesale price per vial is approximately $520; the treatment course costs around $3,120.
- Demand is declining due to changing COVID-19 dynamics, pressuring prices downward.
- Patent expiration slated for 2029 likely to trigger biosimilar competition, with substantial price reductions.
- Regulatory and policy shifts can accelerate or slow market contraction and pricing trends.
- The overall market is poised for gradual decline, but strategic licensing and negotiations could extend Remdesivir’s profitability.
FAQs
1. Will the price of Remdesivir decrease significantly before patent expiry?
Prices are unlikely to decrease substantially before 2029 without policy intervention or market shifts, owing to patent protection and stable demand within hospitals.
2. How will biosimilar entry affect pricing?
Biosimilar entry post-2029 could lead to a 50% or greater reduction in drug prices in markets where biosimilars are permitted and approved.
3. Are there regional price differences for Remdesivir?
Yes, prices vary; in the U.S., the WAC is approximately $520 per vial, while in other regions, government negotiations and procurement policies influence costs.
4. What future therapies could impact Remdesivir’s market?
Oral antivirals such as Paxlovid and Molnupiravir, which are easier to administer, may replace hospital-based treatments, decreasing Remdesivir’s market share.
5. How might policy changes influence Remdesivir's pricing?
Governmental price negotiations, public tenders, and international health initiatives could lead to discounts and volume-based pricing arrangements.
References
[1] Gilead Sciences. (2022). Veklury (Remdesivir) prescribing information.
[2] IQVIA. (2022). Global COVID-19 Treatment Market Data.
[3] European Medicines Agency. (2022). Approval status of Remdesivir.
[4] FDA. (2020). Remdesivir (Veklury) for COVID-19.
[5] Reuters. (2022). Analysis of antiviral drug pricing and market trends.
